CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Menu
Begin main content
Home About What We Do Programs and Services CADTH Reimbursement Review pertuzumab
Back to Programs and Services

CADTH Reimbursement Review

pertuzumab

Last Updated: March 16, 2021
Result type: Reports
Project Number: PC0241-000
Product Line: Reimbursement Review

Generic Name: pertuzumab

Brand Name: Perjeta

Manufacturer: Hoffmann-La Roche Limited

Therapeutic Area: Early stage breast cancer

Indications: Perjeta in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either 2 cm in diameter or node positive).

Manufacturer Requested Reimbursement Criteria1: Pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either 2 cm in diameter or node positive). Patients should receive neoadjuvant treatment with pertuzumab in combination with trastuzumab and chemotherapy for three to six cycles depending on the regimen chosen. Patients who start pertuzumab in combination with trastuzumab and chemotherapy in the neoadjuvant setting and do not have residual disease following surgery should continue to receive adjuvant trastuzumab to complete one year of HER2-directed therapy.

Submission Type: Initial

Tumour Type: Breast

Project Status: Pending

Call for patient/clinician input open: March 16, 2021

Call for patient/clinician input closed: May 7, 2021

Anticipated Date: April 14, 2021

Fee Schedule1: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback